Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewGenIvf GroupNIVF -9.09%14 Return-on-Tangible-Asset is -271.19% as of Dec. 2025. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 680 Healthcare Providers & Services companies, NewGenIvf Group ranks better than 99.41% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NewGenIvf Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $-30.68 Mil. NewGenIvf Group's average total tangible assets for the quarter that ended in Dec. 2025 was $11.31 Mil. Therefore, NewGenIvf Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -271.19%.
The historical rank and industry rank for NewGenIvf Group's Return-on-Tangible-Asset or its related term are showing as below:
NIVF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -13.02 Med: 3.52 Max: 132.73
Current: 103.74
During the past 5 years, NewGenIvf Group's highest Return-on-Tangible-Asset was 132.73%. The lowest was -13.02%. And the median was 3.52%.
NIVF's Return-on-Tangible-Asset is ranked better than 99.41% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs NIVF: 103.74
NewGenIvf Group (NAS:NIVF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
NewGenIvf Group Return-on-Tangible-Asset Related Terms
NewGenIvf Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for NewGenIvf Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIVF vs RHEP, XCRT, SYRA: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, NewGenIvf Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewGenIvf Group Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NewGenIvf Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where NewGenIvf Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -271.19% mean?
NewGenIvf Group (NIVF) has a Return-on-Tangible-Asset of -271.19% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NewGenIvf Group and its competitors. According to the industry distribution chart, NewGenIvf Group ranks #4 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 0.59999999999999%.
Is NewGenIvf Group's Return-on-Tangible-Asset too high?
NewGenIvf Group's current Return-on-Tangible-Asset is -271.19%. Based on the distribution chart, NewGenIvf Group ranks #4 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's Return-on-Tangible-Asset compare to RHEP and XCRT?
According to the Healthcare Providers & Services industry distribution chart, NewGenIvf Group ranks #4 out of 680 companies for Return-on-Tangible-Asset. This places NewGenIvf Group in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NewGenIvf Group and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewGenIvf Group's current Return-on-Tangible-Asset is -271.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current Return-on-Tangible-Asset of -271.19%. The current Return-on-Tangible-Asset is -271.19%. NewGenIvf Group's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current Return-on-Tangible-Asset is -271.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score
Get the complete analysis for NIVF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIVF has been successfully added to your 
